A-425619

A-425619 is an orally active and selective transient receptor potential type V1 (TRPV1) antagonist. A-425619 blocks Capsaicin (HY-10448) - and N-arachidonoyl-dopamine (NADA) -induced Ca2+ influx in dorsal root ganglia and trigeminal ganglia. A-425619 relieves pathophysiological pain associated with inflammation and tissue injury in rats. A-425619 can be used for the study of pain related to inflammation and tissue injury[1][2][3].

Product Specifications

CAS Number

[581809-67-8]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Calcium Channel; TRP Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/a-425619.html

Purity

99.96

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

FC(F)(F)C(C=C1)=CC=C1CNC(NC2=CC=CC3=C2C=CN=C3)=O

Molecular Formula

C18H14F3N3O

Molecular Weight

345.32

Precautions

H315, H319, H320

References & Citations

[1]McDonald HA, et al. Characterization of A-425619 at native TRPV1 receptors: a comparison between dorsal root ganglia and trigeminal ganglia. Eur J Pharmacol. 2008 Oct 31;596 (1-3) :62-9. |[2]El Kouhen R, et al. A-425619 [1-isoquinolin-5-yl-3- (4-trifluoromethyl-benzyl) -urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther. 2005 Jul;314 (1) :400-9. |[3]Honore P, et al. A-425619 [1-isoquinolin-5-yl-3- (4-trifluoromethyl-benzyl) -urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther. 2005 Jul;314 (1) :410-21.